IBAB Ion Beam Applications SA

World's Leading Institutions and IBA launch Proton Therapy Academy to shape the future of cancer care

World's Leading Institutions and IBA launch Proton Therapy Academy to shape the future of cancer care


New global education initiative unveiled at 2025 PTCOG Annual Conference

Louvain-la-Neuve, Belgium, 4 June 2025 - IBA (Ion Beam Applications SA), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces the launch of Proton Therapy Academy, a new global training and education initiative developed in partnership with prominent institutions in the field of proton therapy. The Academy has been unveiled at the 2025 PTCOG (Particle Therapy Co-Operative Group) annual conference, currently taking place in Buenos Aires, Argentina. Visit for more information.

As global demand for proton therapy grows, so does the need for multifaceted training. With many new centers emerging worldwide, The Proton Therapy Academy addresses a critical need for education and training among healthcare professionals. With less than 1% of radiation oncology patients receiving proton therapy globally1 versus a consensus of around 15% needed2, education is a key element to broadening access.

The Proton Therapy Academy will provide and promote access to comprehensive, high-quality education and training programs to the oncology and radiation oncology communities. By empowering healthcare professionals with the knowledge and skills needed to fully leverage this cutting-edge modality, the Academy aims to have proton therapy treatments delivered with the best possible quality, as well as to help close the gap between the current and potential reach of proton therapy.

This new online platform will serve as a central hub for accessing high-quality curated content, lectures, events, and training resources offered by leading organizations in the proton therapy area. The platform has launched with over 135 videos from proton therapy experts.

Prof. Marco Durante, Director of the Biophysics Department at GSI Helmholtz Centre for Heavy Ion Research and President of PTCOG said “The Proton Therapy Academy is a groundbreaking international initiative that unites leading institutions and experts from around the world. By fostering collaboration across continents and among diverse providers, it creates a unique environment for shared learning and innovation. This inclusive model is essential to developing a robust, globally connected community of professionals capable of advancing the field. PTCOG fully supports this cooperative initiative, recognizing its potential to raise the standard of training, encourage cross-border knowledge sharing, and empower the next generation of proton therapy practitioners to shape the future of cancer care.”

“Proton therapy is transforming the landscape of cancer treatment,” said Olivier Legrain, CEO of IBA. “Through the Proton Therapy Academy, we are investing in the global clinical community, ensuring that every oncology professional has access to world-class training, wherever they are. This initiative reinforces IBA’s commitment to advancing cancer care through collaborative innovation and education.”

At the heart of this initiative, is the Proton Therapy Academy Network, a collective of leading cancer treatment institutions from America, Europe, and Asia: Apollo Proton Cancer Center, Corewell Health, The European Institute of Oncology (IEO), Miami Cancer Institute, New York Proton Center, the Paul Scherrer Institute, QuironSalud Proton Therapy Center, the University of Kansas and the University Medical Center Groningen. The network is shaping the Academy’s inaugural training program, which combines theoretical and practical knowledge. This is through a combination of online courses, covering the foundations and clinical applications of proton therapy, as well as on-site training, learning directly from experienced clinical teams at partner institutions.

“As a member of the Proton Therapy Academy Network, we are proud to contribute to a program that blends academic excellence with real-world clinical expertise. Through this collaboration, we are creating accessible, high-quality training that bridges education and clinical practice.” said Prof. Barbara Jereczek-Fossa, Head of the Department of Radiation Oncology at IEO and president-elect of ESTRO. “Training the next generation of proton therapy professionals requires both global perspective and on-site experience. It’s an important step toward making proton therapy more accessible and more effective for patients everywhere.”

***ENDS***

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as the most advanced form of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,100 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at:

CONTACTS

IBA

Olivier Lechien

Corporate Communication Director







1 Yan, S., Ngoma, T. A., Ngwa, W., & Bortfeld, T. R. (2023). Global democratisation of proton radiotherapy. The Lancet Oncology, 24(6), e245-e254. 

2 Burnet, NG et al. Estimating the percentage of patients who might benefit from proton beam therapy instead of X-ray radiotherapy. Br J Radiol. 2022;95(1133):20211175. doi: 10.1259/bjr.20211175.



Attachment



EN
04/06/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ion Beam Applications SA

 PRESS RELEASE

IBA – Transparency Notification - Denominator

IBA – Transparency Notification - Denominator                                                                                                                   June 30th, 2025 Publication made under article 15 of the law of May 2, 2007 relating to the disclosure of major holdings in issuers whose shares are admitted to trading on a regulated market and containing various provisions (Belgian Gazette 12.VI.2007) (hereinafter, the “Law”). Under this provision:  « [...] the issuer publishes the total capital, the total number of securities conferring the right to vote and voting rights, as...

 PRESS RELEASE

IBA – Notification de Transparence - Dénominateur

IBA – Notification de Transparence - Dénominateur 30 juin 2025 Publication effectuée en vertu de l’article 15 de la loi du 2 mai 2007 relative à la publicité des participations importantes dans des émetteurs dont les actions sont admises à la négociation sur un marché réglementé et portant des dispositions diverses (M.B. 12.VI.2007) (ci-après, la « Loi »). En vertu de cette disposition : « [...] l'émetteur publie le total du capital, le nombre total de titres conférant le droit de vote et de droits de vote, ainsi que, par catégorie, le nombre de titres conférant le droit de vote et de ...

Guy Sips ... (+2)
  • Guy Sips
  • Michiel Declercq
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

IBA: Large X-ray sterilisation solution sale Proximus: Stijn Bijnens new CEO of Proximus

 PRESS RELEASE

Steri-Tek to boost sterilization capacity of its Texas-based center fi...

Steri-Tek to boost sterilization capacity of its Texas-based center fivefold with IBA’s X-ray irradiation system Louvain-la-Neuve, Belgium, June 18, 2025 –  (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for industrial advanced irradiation, announced today it has signed a contract with Steri-Tek, a growing irradiation services provider, to install a fully-integrated Be Wide X-ray Solution. IBA’s solution will be installed at Steri-Tek’s service center near Dallas-Fort Worth Metro Area, Texas, which was op...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch